- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03315611
Study to Assess the Effect of "Eucerin AtopiControl" on Dermal Symptoms in Patients With Atopic Dermatitis
Study to Assess the Effect of "Eucerin AtopiControl" on Dermal Symptoms in Patients With Atopic Dermatitis After Challenges With Grass Pollen in the Fraunhofer Allergen Challenge Chamber
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany, 30625
- Fraunhofer ITEM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women will be considered for inclusion if they are: not pregnant, as confirmed by pregnancy test (see flow chart) and not nursing.
Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit). Of childbearing potential and using a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the first dose of study medication until at least 72 hours after the last pollen challenge -, implants, injectables, combined oral contraceptives, hormonal Intra Uterine Devices (IUD) or double-barrier methods, i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap).
- For patient groups 1 and 2: Positive Immunglobulin E (IgE) level for Dactylis glomerata of at least ImmunoCAP fluoroenzyme immunoassay (CAP FEIA) class 3 at screening or within the last 12 months.
- atopic dermatitis fulfilling the United Kingdom (UK) criteria of AD
- SCORAD index between 20 and 50 points.
- Forced expiratory Volume in 1 second (FEV1) ≥ 80% pred. at screening.
- Smokers or non-smokers
- Applicable only for patients of the control group: No IgE-sensitization to grass pollen (including Dactylis glomerata)
Exclusion Criteria:
- Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease.
- Asthma other than mild asthma which is treated with short acting beta-2-agonists only and which is controlled according to the current GINA (Global Initiative for Asthma) guidelines
- Clinically relevant abnormalities in hematology or blood chemistry at screening.
- Positive Human Immunodeficiency Virus Antibody (HIV-1/2Ab), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibodies (HCV-Ab) test at screening.
- Treatment with medication that might interfere with rescue medication for anaphylactic reactions (e.g. beta blocker).
- Topical steroid treatment of air exposed skin (wash out phase: 2 weeks)
- Topical calcineurin inhibitor treatment of air exposed skin (wash out phase: 2 weeks)
- Ultraviolet (UV) radiation treatment (wash out phase: 4 weeks)
- Systemic immunosuppression treatment (steroids, cyclosporine, azathioprine, Mycophenolate Mofetil (MMF); wash out phase: 4 weeks)
- Treatment with antihistamines (wash out phase: 1 week)
- Specific immunotherapy (SIT) with grass pollen allergens within the last 5 years
- Diastolic blood pressure above 95 mmHg.
- Febrile illness within 2 weeks prior to screening.
- Alcohol or drug abuse within 12 month prior to screening.
- Regular daily consumption of more than 1 liter of usual beer or the equivalent quantity of approximately 40 g of alcohol in another form.
- Participation in another clinical trial 30 days prior to enrolment.
- Risk of non-compliance with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: AD, sensitized, treated
Allergen challenge chamber and Treatment for 12 day with 'Eucerin AtopiControl Lotion' (for the body) and 'Eucerin AtopiControl facial cream' (for the face): 1,2 g twice daily.
|
Treatment with Eucerin AtopiControl Lotion
Other Names:
Exposure to Dactylis glomerata pollen in an environmental challenge chamber
|
Experimental: AD, not sensitized, not treated
Allergen challenge chamber
|
Exposure to Dactylis glomerata pollen in an environmental challenge chamber
|
Experimental: AD, sensitized, not treated
Allergen challenge chamber
|
Exposure to Dactylis glomerata pollen in an environmental challenge chamber
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SCORAD Day 3
Time Frame: Day 3: pre- 4 hour-challenge with grass pollen and post-4 hour-challenge with grass pollen
|
Difference of change in objective SCORAD in treated versus untreated patients
|
Day 3: pre- 4 hour-challenge with grass pollen and post-4 hour-challenge with grass pollen
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SCORAD Day 1,2,4,5
Time Frame: Day 1,2,4,5: pre- 4 hour -challenge with grass pollen and post-4 hour-challenge with grass pollen
|
Difference of change in objective SCORAD in treated versus untreated patients
|
Day 1,2,4,5: pre- 4 hour -challenge with grass pollen and post-4 hour-challenge with grass pollen
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jens Hohlfeld, MD, Fraunhofer Gesellschaft
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Otorhinolaryngologic Diseases
- Skin Diseases, Genetic
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Skin Diseases, Eczematous
- Rhinitis, Allergic
- Rhinitis
- Dermatitis
- Eczema
- Rhinitis, Allergic, Seasonal
- Dermatitis, Atopic
Other Study ID Numbers
- 16-09 Neurop 2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on 'Eucerin AtopiControl Lotion' (for the body)
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
Nationwide Children's HospitalNovartisActive, not recruitingSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type IUnited States
-
Jessa HospitalHasselt UniversityRecruitingImmunotoxicity | Skin ToxicityBelgium
-
Hoag Memorial Hospital PresbyterianActive, not recruiting
-
Balgrist University HospitalIndustry (Schülke & Mayr AG, Switzerland and Germany)RecruitingElective Surgery | High Risk | Prevention of Surgical Site Infections | Randomized-controlled TrialSwitzerland
-
University of TorontoCanadian Institutes of Health Research (CIHR)RecruitingStress, Psychological | Stress, PhysiologicalCanada
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Johnson & Johnson Consumer Inc. (J&JCI)CompletedSkin Regeneration After Dermatological Facial Procedure With Fractional CO2 LaserBrazil
-
Zhejiang Cancer HospitalNot yet recruiting
-
Vilnius UniversityKaunas University of TechnologyRecruitingAlcohol Drinking | Sleep Disorder | Stress | Atrial Fibrillation | Sleep Apnea | Atrial Flutter | Arterial Hypertension | Physical Inactivity | Atrial Tachycardia | Atrial Arrhythmia | Caffeine Dependence | Premature Atrial Contractions | OverexertionLithuania